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Changes in Antimicrobial Usage 
Patterns in Korea: 12-Year Analysis 
Based on Database of the National 
Health Insurance Service-National 
Sample Cohort
Young Ah Kim1, Yoon Soo Park2, Taemi Youk3, Hyukmin Lee4 & Kyungwon Lee4
National antimicrobial usage and prescription patterns during the 12 years from 2002 to 2013 were 
analyzed using the National Health Insurance Service-National Sample Cohort. Antimicrobial usage 
was analyzed by major illness, sex, age, area of residence, income rank, diagnosis, and type of medical 
institution for each year. Total antimicrobial prescriptions increased from 15.943 daily defined dose 
(DDD)/1,000 inhabitants/day in 2002 to 24.219 in 2013. In 2013, 72% of total prescriptions were 
administered in clinics. Antimicrobials were most frequently prescribed to children younger than 10 
years, followed by adults aged 70 years or older and those aged 60–69 years. Penicillins and cephems 
were the most popular classes of antimicrobial used. In 2013, 48% of total antibiotic usage (11.683 
DDD/1,000 inhabitants/day) was due to respiratory diseases. After the Korean government has 
implemented a series of healthcare policies, antibiotic prescription decreased for the treatment of 
upper respiratory infection, the causative agents are mostly viruses.
Although antibiotics have saved the lives of millions of people worldwide since the discovery of penicillin in 1928, 
the emergence of antibiotic resistance in bacteria is a serious global challenge. Antibiotic resistance develops 
when bacteria adapt and grow in the presence of antibiotics. Because the development of resistance is linked to 
how often antibiotics are used, misuse and over-use of antibiotics hasten the development of bacterial drug resist-
ance, rendering existing antibiotics less effective1–3. Although infection by multidrug-resistant bacteria poses a 
grave threat to public health and wellbeing through subsequent increases in hospital stays, medical costs, and 
mortality4–6, the development of new antimicrobials is a practically challenging task.
Because bacterial resistance is increasing and the development of new antimicrobial is declining, securing the 
efficacy of existing antibiotics for long periods of time is the key to solving the antimicrobial resistance problem. 
In other words, the key is to suppress the occurrence of bacterial resistance in existing antibiotics. In 2015, World 
Health Organization (WHO) adopted a global action plan on antimicrobial resistance, which declared it as an 
urgent public health concern and emphasized prudent antimicrobial prescriptions in human and animal health, 
based on evidence and the current epidemiology1.
Although the prevalence of antimicrobial resistance in Korea is higher than that in advanced countries such as 
the United States and Europe7,8, studies on the changes in antimicrobial usage patterns, which drive antimicrobial 
management policies, were limited in terms of research institutions, regions, and medical facilities9–16. The aim of 
this study was to analyze antimicrobial usage and prescription patterns at the national level in Korea during the 
12-year period from 2002 to 2013. We expect the findings to help identify the major groups in need of interven-
tion and provide grounds for developing public health policies to manage antimicrobial usage.
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Methods
Analysis of antimicrobial usage and prescription patterns. We analyzed national antimicrobial 
usage and prescription patterns during the 12 years from 2002 to 2013 using the National Health Insurance 
Service-National Sample Cohort (NHIS-NSC)17. The data obtained from the national health database consisted of 
a national sample of 1,025,340 people (males: 513,258, females: 512,082), accounting for 2.2% of the total Korean 
population as of the 2002 census.
Systematic stratified sampling was used based on sex, age, and type of health insurance, and the data include 
socioeconomic variables (e.g., area of residence, income rank, disability), mortality, healthcare use (e.g., medical 
bills, details of care, diagnosis, and prescription), and health examination data.
Antimicrobials were classified as penicillins, cephems, carbapenems, fluoroquinolones, aminoglycosides, tet-
racyclines, macrolides, glycopeptides, or folate path inhibitors for analysis. Antimicrobial usage was analyzed 
by income rank (5 ranks), which was determined using insurance bills per household, by medical institution 
(general hospital, hospital, long-term care hospital, clinic), and by region (17 cities and provinces). Following 
medical law in Korea, we classified medical institutions as clinics if they had fewer than 30 beds, as hospitals if 
they had more than 30 beds, and as general hospitals if they had more than 100 beds. A long-term care hospital 
was defined as a nursing hospital if it was intended for patients with geriatric or chronic diseases or patients who 
require postoperative recovery.
Upper respiratory infection (URI) was included as a major illness for analysis of antimicrobial usage patterns. 
URI, which involves viral pathogens in most cases, rarely requires antimicrobials for treatment and is associated 
with antimicrobial abuse. Bacterial pneumonia and urinary tract infections require antimicrobial prescriptions, 
and the incidence of these diseases is increasing with the growing elderly population. The major illnesses analyzed 
in this study, according to the Korean Standard Classification of Diseases, were respiratory diseases (code J) and 
genitourinary diseases (code N); more specifically, we analyzed URIs (J00-J06), pneumonia (J13-J17), and uri-
nary tract infections (N10-N12, N136, N151, N159, N20-N21, N30, N34, N390).
Because the dose, form, and frequency of use vary across antimicrobial products, the daily defined dose 
(DDD) and yearly antimicrobial usage by active ingredient were calculated as follows to measure standardized 
usage.
days
Antimicrobial usage by active ingredient (DDD/1,000 inhabitants/day)
Amount of antimicrobials used for a year (mg)
WHO DDD (mg) 365 sample population of the year
1,000 inhabitants=
− × ×
×
This describes the number of people (per a population of 1,000) who use an antimicrobial every day. As an 
example, 10 DDD per 1,000 inhabitants per day means that 1% of the population, on average, might receive a cer-
tain drug or group of drugs daily. Antimicrobial usage was analyzed by sex, age, area of residence, income rank, 
diagnosis, and type of medical institution for each year.
Statistical analysis. Trend tests were performed to determine potential differences in antimicrobial usage 
by year, and linear mixed models using group, time, and group-by-time as fixed effects were used to identify 
potential differences in the yearly patterns of antimicrobial usage in relation to general characteristics. Data were 
organized and analyzed using SAS v9.4 software (SAS Institute Inc., Cary, NC, USA).
Results
Antimicrobial prescriptions. Total antimicrobial prescriptions in Korea increased from 15.943 DDD/1,000 
inhabitants/day in 2002 to 24.219 in 2013 (Table 1, P < 0.001). By class, penicillins were the most frequently 
prescribed, followed by cephems, including cephalosporin and cephamycin (Fig. 1). No changes in penicillin 
prescription patterns occurred over the course of the 12-year period (P = 0.661). Cephem, carbapenem, fluoro-
quinolone, tetracycline, macrolide, and glycopeptide prescriptions increased, and aminoglycoside and folate path 
inhibitor prescriptions decreased (Table 1, P < 0.001).
Data from 2013 were examined to identify the antimicrobials most frequently prescribed in recent years. The 
total penicillin prescription rate was 7.768 DDD/1,000 inhabitants/day, and antimicrobials containing amoxicillin 
were the most frequently used. Amoxicillin was popular in 2002, but amoxicillin-clavulanate was more frequently 
used by 2013 (in DDD/1,000 inhabitants/day: amoxicillin 5.214, amoxicillin-clavulanate 1.777 in 2002; amoxi-
cillin 2.250, amoxicillin-clavulanate 4.943, amoxicillin-sulbactam 0.394 in 2013). Among the cephems, cefaclor 
(3.222) was the most frequently prescribed, followed by cefuroxime (0.837), and cephradine (0.438). These three 
drugs accounted for 61% of all cephem prescriptions (7.211). Among fluoroquinolones, levofloxacin (0.978) 
was the most frequently prescribed, followed by ciprofloxacin (0.675), and ofloxacin (0.594). These three drugs 
accounted for 89% of the total fluoroquinolone prescriptions (2.565). The total macrolide prescriptions equaled 
3.392 DDD/1,000 inhabitants/day, consisting of clarithromycin (1.896), roxithromycin (1.301), and azithromycin 
(0.193). For tetracycline, aminoglycoside, folate path inhibitor, carbapenem, and glycopeptide, 1.334, 0.807, 0.14, 
0.055, and 0.053 DDD/1,000 inhabitants/day were prescribed, respectively.
Regarding the types of medical institutions, the vast majority of antimicrobials were prescribed in clinics, 
followed by general hospitals, hospitals, and long-term care hospitals (Fig. 2). In 2013, 72% of total prescrip-
tions occurred in clinics (Table 2). Among clinics, penicillins (6.378 DDD/1,000 inhabitants/day) were the most 
frequently prescribed antimicrobial, followed by cephems (4.796), macrolides (2.639), and fluoroquinolones 
(1.536). In general hospitals, cephems (1.443) were the most frequently prescribed antimicrobial, followed by 
fluoroquinolones (0.767), penicillins (0.635), and macrolides (0.488) (Table 2). Antimicrobial prescriptions of all 
classes, except for that of penicillin in clinics (P = 0.111), increased every year regardless of medical institution 
(Table 2).
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Antimicrobial prescriptions by sociodemographic features. No difference was observed in the use 
of antimicrobials according to gender (Fig. 3, P = 0.54), with antimicrobial prescription increasing every year in 
both males and females (Fig. 3, P < 0.001). The use of antimicrobials varied with age group (Fig. 4, P < 0.001). 
Antimicrobials were most frequently prescribed to children younger than 10 years, followed by adults aged 70 
years or older and those aged 60–69 years (Fig. 4). In 2013, penicillins were the most frequently prescribed anti-
microbial in children younger than 10 years, followed by cephems and macrolides, whereas cephems were the 
most frequently prescribed antimicrobial in adults aged 70 years or older, followed by fluoroquinolones, penicil-
lins, and macrolides (data not shown).
When antimicrobial prescription patterns were analyzed by stratifying the income levels of the sample into 
five groups (from the upper 20th percentile to the lower 20th percentile), no difference was found according to 
income level (Fig. 5, P = 0.65), with antimicrobial prescriptions increasing every year in all five income groups 
(Fig. 5, P < 0.001). Areas of residence were classified into 17 cities and provinces using the subjects’ addresses on 
resident registrations to examine differences in antimicrobial prescription patterns across regions. Antimicrobial 
prescriptions increased in all cities and provinces (P < 0.001), without regional differences (P = 0.47, data not 
shown).
Class 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 P
Penicillin 7.654(48)
7.228
(44)
8.207
(46)
8.868
(46)
8.484
(42)
7.796
(38)
8.640
(36)
8.273
(34)
8.527
(33)
7.990
(32)
8.008
(32)
7.768
(32) 0.661
Cephem 3.245(20)
3.535
(21)
3.883
(21)
4.385
(22)
4.930
(24)
5.343
(26)
6.575
(27)
6.723
(28)
7.241
(28)
7.134
(28)
7.327
(29)
7.211
(29) <0.001
Carbapenem 0.003(0)
0.008
(0)
0.013
(0)
0.016
(0)
0.024
(0)
0.029
(0)
0.036
(0)
0.033
(0)
0.041
(0)
0.045
(0)
0.051
(0)
0.055
(0) <0.001
Fluoroquinolone 1.445(9)
1.665
(10)
1.730
(9)
1.891
(9)
1.953
(9)
2.225
(10)
2.630
(10)
2.567
(10)
2.578
(10)
2.614
(10)
2.669
(10)
2.565
(10) <0.001
Tetracycline 0.406(2)
0.427
(2)
0.434
(2)
0.459
(2)
0.581
(2)
0.857
(4)
1.102
(4)
1.161
(4)
1.270
(5)
1.301
(5)
1.336
(5)
1.334
(5) <0.001
Macrolide 0.999(6)
1.263
(7)
1.440
(8)
1.724
(8)
1.970
(9)
2.300
(11)
2.850
(11)
3.067
(12)
3.450
(13)
3.627
(14)
3.583
(14)
3.392
(14) <0.001
Glycopeptide 0.006(0)
0.011
(0)
0.014
(0)
0.015
(0)
0.020
(0)
0.029
(0)
0.038
(0)
0.034
(0)
0.039
(0)
0.043
(0)
0.047
(0)
0.053
(0) <0.001
Aminoglycoside 1.494(9)
1.266
(7)
1.204
(6)
1.166
(6)
1.062
(5)
1.047
(5)
1.049
(4)
1.017
(4)
0.973
(3)
0.951
(3)
0.838
(3)
0.807
(3) <0.001
Folate path inhibitor 0.231(1)
0.249
(1)
0.218
(1)
0.201
(1)
0.182
(0)
0.176
(0)
0.179
(0)
0.155
(0)
0.155
(0)
0.150
(0)
0.145
(0)
0.140
(0) <0.001
Total amount 15.943 16.142 17.656 19.272 19.753 20.482 23.958 23.836 25.107 24.732 24.899 24.219 <0.001
Table 1. Antimicrobial prescription according to class of antimicrobials (DDD/1,000 inhabitants/days). All 
classes of antimicrobial were included in total amount. (% of total DDD).
Figure 1. Average antimicrobial prescription according to class of antimicrobials from 2002 to 2013 (DID: 
Daily Defined Dose/1,000 inhabitants/days).
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Antimicrobial prescriptions by major illness. For major illness prescribed for antimicrobials, more than 
half of all antimicrobial agents used were due to respiratory diseases (Fig. 6). Antimicrobial prescriptions for 
respiratory diseases increased every year (Table 3, P < 0.001). In 2013, 48% (11.683 DDD/1,000 inhabitants/day) 
of total antibiotic usage was due to respiratory diseases. Although not statistically significant, antimicrobial pre-
scriptions for URIs decreased from 4.9 DDD/1,000 inhabitants/day in 2002 to 3.625 in 2013 (P = 0.109, Table 3). 
Antimicrobial prescriptions for genitourinary diseases, including urinary tract infections, increased every year 
(Table 3, P < 0.001).
By class, penicillins were the most frequently prescribed antimicrobial for respiratory diseases (5.281 
DDD/1,000 inhabitants/day) in 2013, followed by cephems (3.113), macrolides (2.307), and fluoroquinolones 
(0.697), and similar trend was observed for URIs. For genitourinary diseases, fluoroquinolones were the most 
frequently prescribed antibiotics (0.796), followed by cephems (0.488), and a similar trend was observed for 
urinary tract infections.
When antibiotic use was compared between 2013 and 2002, cephem, macrolide and fluoroquinolone use 
increased, but penicillin use was not increased for respiratory diseases. For genitourinary diseases, prescription 
of cephem, macrolide, penicillin and fluoroquinolone increased (see Table 3).
Discussion
This study explored the changes of antimicrobial usage in Korea from 2002 to 2013 through analyzing the 
NHIS-NSC data using DDD developed by the WHO for drug statistics methodology.
Antimicrobial resistance in human pathogens shows substantial geographic differences across the globe. 
Although antimicrobial resistance remains low in Northern European countries, it is high in Southern 
European, Latin American and Asian countries. In Asia, extended spectrum β-lactamase (ESBL)-producing 
Enterobacteriaceae are of concern and are increasing. In 2009 and 2010, 28 percent of Enterobacteriaceae iso-
lated from the patients with urinary tract infections in 11 countries were ESBL producers18. In China, in 2011, 
ESBL-producing E. coli accounted for 71 percent of E. coli isolates, and more than half of K. pneumoniae strains 
produced ESBL19. Infections with carbapenem-resistant Enterobacteriaceae are increasingly reported from 
healthcare facilities, not only in developed countries20, but also in low- and middle income countries. Treatment 
for carbapenem-resistant Enterobacteriaceae is much more complicated than ESBL-producing stains because of 
limited treatment options.
Between 2000 and 2010, global consumption of antibiotic drugs increased by 36%21. There is a high varia-
bility of antimicrobial consumption across countries. Among the Organisation for Economic Co-operation and 
Development (OECD) countries, Chile and Netherlands reported the lowest volume (9.4 and 11.4 DDD/1,000 
inhabitants/day, respectively) and Greece and Italy reported 30.1 and 34.9 DDD/1,000 inhabitants/day, respec-
tively in 201322. Antimicrobial use in Japan was 14.7 in 2009 and 15.8 DDD/1,000 inhabitants/day23. Korea 
remains a country with heavy antimicrobial usage16,24; its 2013 national average (28.4 DDD/1,000 inhabitants/
day) exceeds the OECD average (20.4 DDD/1,000 inhabitants/day)22. New systems were introduced in Korea 
upon the turn of the 21st century to increase the quality of medicine and reduce the use of antimicrobials25,26, 
including the separation of dispensing and prescribing in 2000, drug-use assessment (including antimicrobials) 
in 2001, public reporting of the rate of antibiotics use for URI in 2006, and assessment of antimicrobial use for 
surgical prophylaxis27.
Figure 2. Average antimicrobial prescription according to types of medical institutions from 2002 to 2013 
(DID: Daily Defined Dose/1,000 inhabitants/days).
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Medical institution Class 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 P
Clinics
Penicillin 7.252(51)
6.579
(49)
7.367
(52)
7.839
(52)
7.331
(49)
6.725
(43)
7.467
(40)
7.045
(38)
7.242
(38)
6.683
(37)
6.650
(36)
6.378
(36) 0.111
Cephem 2.735(19)
2.692
(20)
2.805
(19)
3.035
(20)
3.047
(20)
3.625
(23)
4.628
(25)
4.783
(26)
5.078
(26)
4.769
(26)
4.919
(27)
4.796
(27) <0.001
Fluoroquinolone 1.154(8)
1.260
(9)
1.277
(9)
1.357
(9)
1.384
(9)
1.573
(10)
1.879
(10)
1.759
(9)
1.678
(8)
1.628
(9)
1.644
(9)
1.536
(8) 0.006
Macrolide 0.796(5)
0.913
(6)
1.028
(7)
1.235
(8)
1.415
(9)
1.700
(10)
2.191
(10)
2.374
(13)
2.679
(14)
2.763
(15)
2.779
(15)
2.639
(15) <0.001
Subtotal amount 14.096(88)
13.258
(82)
14.158
(80)
15.062
(78)
14.728
(74)
15.457
(75)
18.339
(76)
18.134
(76)
18.892
(75)
18.043
(72)
18.111
(72)
17.417
(72) <0.001
Hospitals
Penicillin 0.088(34)
0.184
(34)
0.296
(35)
0.410
(35)
0.415
(34)
0.409
(29)
0.476
(28)
0.511
(28)
0.572
(28))
0.596
(26)
0.649
(27)
0.702
(29) <0.001
Cephem 0.078(30)
0.162
(30)
0.262
(31)
0.367
(32)
0.392
(32)
0.473
(34)
0.615
(36)
0.660
(36)
0.761
(37)
0.877
(38)
0.922
(38)
0.923
(38) <0.001
Fluoroquinolone 0.025(9)
0.063
(11)
0.094
(11)
0.118
(10)
0.126
(10)
0.153
(11)
0.177
(10)
0.190
(10)
0.204
(10)
0.222
(9)
0.245
(10)
0.241
(9) <0.001
Macrolide 0.018(7)
0.045
(8)
0.062
(7)
0.087
(7)
0.106
(8)
0.123
(8)
0.161
(9)
0.192
(10)
0.227
(9)
0.272
(12)
0.278
(11)
0.255
(10) <0.001
Subtotal amount 0.252(1)
0.540
(3)
0.844
(4)
1.144
(5)
1.218
(6)
1.382
(6)
1.692
(7)
1.819
(7)
2.040
(8)
2.256
(9)
2.390
(9)
2.417
(9) <0.001
General hospitals
Penicillin 0.313(19)
0.426
(18)
0.494
(19)
0.552
(18)
0.653
(18)
0.569
(16)
0.611
(16)
0.627
(17)
0.636
(15)
0.643
(15)
0.648
(15)
0.635
(15) 0.001
Cephem 0.431(27)
0.671
(29)
0.796
(31)
0.953
(32)
1.438
(39)
1.174
(34)
1.272
(34)
1.221
(33)
1.345
(33)
1.434
(33)
1.432
(33)
1.443
(34) <0.001
Fluoroquinolone 0.265(16)
0.336
(12)
0.350
(13)
0.403
(13)
0.424
(11)
0.470
(13)
0.553
(13)
0.598
(16)
0.675
(16)
0.745
(17)
0.758
(17)
0.767
(18) <0.001
Macrolide 0.185(11)
0.303
(13)
0.346
(13)
0.395
(13)
0.436
(12)
0.465
(13)
0.488
(14)
0.489
(13)
0.532
(13)
0.582
(13)
0.515
(12)
0.488
(11) <0.001
Subtotal amount 1.593(9)
2.280
(14)
2.564
(14)
2.934
(15)
3.614
(18)
3.403
(16)
3.727
(15)
3.679
(15)
3.982
(15)
4.258
(17)
4.225
(16)
4.228
(17) <0.001
Long-term care 
hospitals
Penicillin 0.000 0.001(20)
0.004
(28)
0.010
(29)
0.017
(26)
0.026
(22)
0.017
(23)
0.020
(26)
0.022
(25)
0.020
(24)
0.020
(23)
0.018
(20) 0.003
Cephem 0.000 0.002(40)
0.004
(28)
0.011
(32)
0.021
(32)
0.041
(32)
0.028
(39)
0.028
(36)
0.031
(36)
0.031
(37)
0.031
(36)
0.032
(36) 0.001
Fluoroquinolone 0.000 0.001(20)
0.002
(14)
0.005
(14)
0.008
(12)
0.018
(15)
0.008
(11)
0.008
(10)
0.011
(12)
0.011
(13)
0.014
(16)
0.015
(17) 0.002
Macrolide 0.000 0.000 0.001(7)
0.002
(5)
0.004
(6)
0.004
(3)
0.003
(4)
0.004
(5)
0.004
(4)
0.004
(4)
0.003
(3)
0.004
(4) 0.004
Subtotal amount 0.001(0)
0.005
(0)
0.014
(0)
0.034
(0)
0.065
(0)
0.117
(0)
0.071
(0)
0.076
(0)
0.086
(0)
0.083
(0)
0.086
(0)
0.087
(0) <0.001
Total amount 15.943 16.142 17.656 19.272 19.753 20.482 23.958 23.836 25.107 24.732 24.899 24.219 <0.001
Table 2. Antimicrobial prescription according to medical institution (DDD/1,000 inhabitants/days). All classes 
of antimicrobial were included in total amount. (% of subtotal DDD or % of total DDD).
Figure 3. Antimicrobial prescription according to sex from 2002 to 2013.
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The changing patterns of antibiotics usage in Korea have been reported from the past28. A study that compared 
antimicrobial usage in Korea before and after the separation of dispensing and prescribing in July 2000 reported 
that antimicrobial usage before the separation was 28.1 DDD/1,000 inhabitants/day in 1998 and 30.8 in 1999, 
which decreased to 19.8 in 2001 and 17 in 2002 after the separation25. Studies that analyzed antimicrobial usage 
Figure 4. Antimicrobial prescription according to age group from 2002 to 2013.
Figure 5. Antimicrobial prescription according to income levels of the sample into five groups (from upper 20 
percentiles to lower 20 percentiles) from 2002 to 2013.
Figure 6. Average antimicrobial prescription according to major illness from 2002 to 2013 (DID: Daily Defined 
Dose/1,000 inhabitants/days; URI: upper respiratory tract infection).
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after the separation of dispensing and prescribing drugs using health insurance found that usage was 23.62 in 
200411. A previous study, ‘Annual Products of Medicine in 2008′, analyzed the cost and amounts of antibiotics 
produced and compared them with previous data. The cost and amounts of antibiotics are indirect parameters of 
drug utilization, and that study did not consider imported antibiotics. In this study, the DDD was used because it 
facilitates the presentation and comparison of drug consumption statistics at international, national and regional 
levels. Although drug consumption can be measured in cost, number of units, number of prescriptions or the 
physical quantity of drugs, these variables can vary between regions and countries over time. Because of such 
limitation in comparisons of drug consumption at an international level, a technical unit of measurement, DDD, 
is recommended by the WHO to measure drug utilization in countries29. Moreover, the NHIS-NSC data used in 
this study were claim data that could be used to estimate nationwide antibiotics usage directly14.
This study found that antimicrobial usage increased, from 15.943 DDD/1,000 inhabitants/day in 2002 to 
24.219 in 2013. Analysis of usage by year showed a sharp increase from 2002 to 2010, but had been consistent 
since 2010. Since antimicrobial usage is increasing despite the enforcement of relevant policies, it can be sus-
pected that these policies are not effective enough, or that the growth of the elderly population has increased 
antimicrobial usage. However, the rate at which antibiotics use increases is declining in recent years, and it seems 
that the antibiotic policy is beginning to show its effects.
URI, a disease that encompasses simple colds, allergic rhinitis, middle ear infections, and pharyngitis, is viral 
in most cases, and antimicrobials are rarely required, suggesting that antimicrobial usage for this particular dis-
ease should be managed closely30. Although changing prescribing behaviors can be difficult, guidelines exist for 
acute rhinosinusitis31, acute uncomplicated bronchitis32, and pharyngitis33, and proven evidence-based methods 
can be used to optimize antibiotic therapy in outpatient settings34–36.
Illness Class 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 P
Respiratory disease
Cephem 1.919(21)
1.813
(21)
1.868
(20)
2.059
(20)
2.216
(22)
2.308
(23)
3.042
(24)
3.270
(26)
3.391
(26)
3.105
(25)
3.234
(26)
3.113
(26) <0.001
Macrolide 0.686(7)
0.838
(10)
0.952
(10)
1.150
(11)
1.305
(13)
1.557
(15)
1.973
(16)
2.167
(17)
2.418
(18)
2.559
(21)
2.498
(20)
2.307
(19) <0.001
Penicillin 4.922(54)
4.431
(53)
5.125
(56)
5.651
(56)
5.232
(53)
5.030
(50)
5.895
(48)
5.755
(46)
5.835
(45)
5.345
(44)
5.441
(44)
5.281
(45) 0.075
Fluoroquinolone 0.519(5)
0.503
(6)
0.498
(5)
0.559
(5)
0.543
(5)
0.604
(6)
0.764
(6)
0.745
(6)
0.700
(5)
0.694
(5)
0.737
(6)
0.697
(5) <0.001
Subtotal amount 9.002(56)
8.265
(51)
9.032
(51)
9.988
(51)
9.777
(49)
9.968
(48)
12.171
(50)
12.390
(51)
12.759
(50)
12.074
(48)
12.232
(49)
11.683
(48) <0.001
   Upper respiratory 
tract infection
Cephem 1.012(20)
0.928
(21)
0.934
(20)
1.028
(20)
0.855
(21)
0.935
(23)
1.229
(24)
1.269
(26)
1.289
(26)
1.045
(26)
1.029
(26)
0.963
(26) 0.264
Macrolide 0.266(5)
0.269
(6)
0.297
(6)
0.367
(7)
0.334
(8)
0.394
(9)
0.529
(10)
0.566
(11)
0.644
(13)
0.558
(13)
0.557
(14)
0.504
(13) <0.001
Penicillin 2.879(58)
2.520
(58)
2.839
(62)
3.106
(62)
2.438
(60)
2.316
(57)
2.776
(56)
2.603
(54)
2.562
(53)
2.128
(53)
2.054
(52)
1.951
(53) 0.005
Fluoroquinolone 0.243(4)
0.226
(5)
0.208
(4)
0.225
(4)
0.189
(4)
0.198
(4)
0.241
(4)
0.225
(4)
0.193
(4)
0.160
(4)
0.156
(4)
0.132
(3) 0.003
Subtotal amount 4.900(30)
4.279
(26)
4.552
(25)
4.982
(25)
4.000
(20)
4.012
(19)
4.949
(20)
4.817
(20)
4.824
(19)
3.999
(16)
3.886
(15)
3.625
(14) 0.109
Genito-urinary disease
Cephem 0.173(12)
0.233
(14)
0.258
(16)
0.297
(18)
0.330
(19)
0.388
(19)
0.460
(19)
0.453
(19)
0.471
(20)
0.479
(20)
0.484
(20)
0.488
(21) <0.001
Macrolide 0.024(1)
0.029
(1)
0.028
(1)
0.034
(2)
0.048
(2)
0.052
(2)
0.061
(2)
0.061
(2)
0.067
(2)
0.070
(2)
0.077
(3)
0.074
(3) <0.001
Penicillin 0.382(27)
0.381
(23)
0.361
(22)
0.354
(21)
0.327
(18)
0.255
(12)
0.229
(9)
0.203
(8)
0.192
(8)
0.185
(7)
0.172
(7)
0.167
(7) <0.001
Fluoroquinolone 0.352(25)
0.482
(30)
0.502
(31)
0.532
(32)
0.566
(32)
0.668
(34)
0.829
(34)
0.814
(35)
0.829
(35)
0.847
(35)
0.843
(35)
0.796
(34) <0.001
Subtotal amount 1.381(8)
1.593
(9)
1.589
(8)
1.646
(8)
1.724
(8)
1.979
(9)
2.372
(9)
2.322
(9)
2.341
(9)
2.383
(9)
2.382
(9)
2.302
(9) <0.001
  Urinary tract infection
Cephem 0.057(10)
0.073
(11)
0.078
(12)
0.088
(13)
0.096
(13)
0.114
(14)
0.138
(14)
0.140
(15)
0.152
(16)
0.157
(16)
0.170
(17)
0.182
(19) <0.001
Macrolide 0.015(2)
0.015
(2)
0.015
(2)
0.018
(2)
0.021
(3)
0.022
(2)
0.023
(2)
0.022
(2)
0.025
(2)
0.023
(2)
0.026
(2)
0.025
(2) <0.001
Penicillin 0.080(14)
0.093
(14)
0.089
(13)
0.086
(12)
0.084
(12)
0.076
(9)
0.072
(7)
0.064
(7)
0.065
(6)
0.065
(6)
0.063
(6)
0.061
(6) <0.001
Fluoroquinolone 0.177(32)
0.245
(37)
0.248
(38)
0.272
(40)
0.282
(40)
0.333
(41)
0.404
(43)
0.388
(43)
0.411
(43)
0.426
(45)
0.434
(44)
0.412
(43) <0.001
Subtotal amount 0.542(3)
0.656
(4)
0.641
(3)
0.671
(3)
0.700
(3)
0.801
(3)
0.923
(3)
0.892
(3)
0.938
(3)
0.940
(3)
0.968
(3) 0.942 (3) <0.001
Total amount 15.943 16.142 17.656 19.272 19.753 20.482 23.958 23.836 25.107 24.732 24.899 24.219 <0.001
Table 3. Antimicrobial prescription according to illness (DDD/1,000 inhabitants/days). All classes of 
antimicrobial were included in total amount. (% of subtotal DDD or % of total DDD).
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Over the last decade the Korean government has implemented a series of healthcare policies directed to URI 
consisting of drug utilization review in the outpatient service in 2001 and public reporting of the rate of antibiot-
ics use for URI in 2006. As a result of government policy for URI, antimicrobial usage for URIs tended to decline, 
though the trend was not statistically significant, from 4.9 DDD/1,000 inhabitants/day in 2002 to 3.625 in 2013. 
The proportion of total antimicrobial usage for acute URIs decreased from 30% in 2002 to 14% in 2013. In par-
ticular, antimicrobials prescribed for URI decreased after public reporting of the rate of antibiotics use for URI in 
2006 (4.982 in 2005 and 4.000 in 2006).
Perception change of primary physician and a public campaign for ‘appropriate antibiotic use’ could contrib-
ute to decrease of antimicrobial usage. Studies using clinical scenarios involving the common cold or standard 
patients showed that physicians’ responses in favor of antibiotic prescription in acute URTIs fell from 75.0% in 
1991 to 54.7% in 2003 and to 27.2% in 2010 although the clinical cases and study subjects differed between the 
studies37–40. A public campaign for ‘appropriate antibiotic use’ organized by the Korean Society of Infectious 
Diseases and the Korean Society for Chemotherapy, and sponsored by the Korea CDC, was launched in Korea 
in 201141.
In 2008, the use of antimicrobials increased significantly. After the implementation of public reporting in 2006, 
diagnostic coding which has not been designated for antibiotic use evaluation were increased significantly. For 
example, the most common respiratory tract infections was J03 acute tonsillitis in 2005 but changed to J20 acute 
bronchitis in 2009. Increased use of antimicrobials in 2008 may be explained in part by diagnostic shift in the 
outpatient setting although the cause of increasing trends in total antimicrobial usage needs to be determined27.
The use of aminoglycosides decreased from 1.494 in 2002 (10% of total antimicrobial usage) to 0.807 
in 2013 (3% of total antimicrobial usage). Although amoxicillin was the most popular penicillin in 2002, 
amoxicillin-clavulanate was more popular in 2013, suggesting a preference for combined drugs to overcome bac-
terial resistance. Whereas the use of penicillins did not increase, the use of cephems increased more than two-fold 
over our study period. Cephem use was only half of that of penicillins in 2002, but prescriptions increased to 
a level comparable with that of penicillins in 2013. The most frequently used cephem was cefaclor; its usage in 
2013 was 3.222 DDD/1000 inhabitants/day, which accounted for half of the total cephem usage (7.211). The 
fact that the use of cefaclor, a second-generation cephem, exceeded that of oral third-generation cephems such 
as cefixime and cefpodoxime (though their use increased as well) could be related to insurance policies that do 
not cover primary treatment with third-generation cephems. Furthermore, the side effects (e.g., diarrhea) of 
amoxicillin-clavulanate, which is used to overcome resistance, could contribute to the preference for cefaclor. 
Macrolide and fluoroquinolone prescriptions also increased, and prescriptions for clarithromycin, levofloxacin, 
and ciprofloxacin increased by particularly high degrees. Use of sulfamethoxazole-trimethoprim, a drug typically 
used to treat urinary tract infections, declined, possibly due to concerns of resistance of Escherichia coli—the most 
common pathogen in urinary tract infections.
Regarding age, antimicrobials were most heavily used in children under the age of 10, followed by adults aged 
70 years or older and those aged 60–69 years. Penicillins were the most popular antimicrobial among children. 
Fluoroquinolones are not used in children due to the potential side effects. Cephems were preferred over peni-
cillins among adults aged 20 years or older, and cephems and fluoroquinolones were preferred over penicillins 
among adults aged 70 years or older in 2013.
In this study analyzed all antimicrobial used, there was no difference was found according to income level. 
Recent study for antimicrobial used for acute URIs found that income level was negatively correlated with pre-
scription rate and suggested demand factors as well as supply factors contributed antibiotic overuse15. We hypoth-
esize that demand factors have a greater impact on mild illnesses such as acute URIs.
In 2013, 72% of total prescriptions occurred in clinics. This is attributable to the fact that a greater number 
of patients are treated in clinics than in other types of medical institutions. Thus, antimicrobial usage in clinics 
should be closely monitored.
In conclusion, antimicrobial usage increased in Korea from 2002 to 2013, with 70% of the prescriptions made 
in clinics, and penicillins and cephems being the most popular classes of antimicrobials. In 2013, 48% of all 
antimicrobials were prescribed for respiratory diseases, and antimicrobial prescriptions for URIs are declining. 
On the cusp of a post-antibiotics era, monitoring antimicrobial use can be an important strategy to prolong the 
activities of existing antimicrobials.
Data availability. The datasets generated during the current study are available from the corresponding 
author on reasonable request.
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